Skip to main content
. 2023 Feb 27;61:102635. doi: 10.1016/j.redox.2023.102635

Fig. 8.

Fig. 8

TLK199 aggravated bone loss in OVX mice in vivo, whereas rGSTP1 dose the opposite. (A) Flowchart of the animal experiments. (B) Representative Micro-CT images of mice in the sham, OVX and OVX + TLK199 groups after one month. (C) Quantitative analysis of bone volume/tissue volume (BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp) and trabecular number (Tb.N). (D) TRAP staining of the distal femur slices in the sham-operated group, the OVX group and the OVX + TLK199 group after one month (fast green as the background color). (E) Representative Micro-CT images of mice in the SHAM, OVX and OVX + rGSTP1 groups after two month. (F) Quantitative analysis of bone volume/tissue volume (BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp) and trabecular number (Tb.N). (G) TRAP staining of the distal femur slices in the SHAM-operated, the OVX and the OVX + rGSTP1 groups after two month. All data are presented as mean ± SEM. Experimental data for each quantitative analysis were replicated at least three times. *P < 0.05, **P < 0.01, ***P < 0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)